CN105641511A - Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof - Google Patents
Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN105641511A CN105641511A CN201610023812.7A CN201610023812A CN105641511A CN 105641511 A CN105641511 A CN 105641511A CN 201610023812 A CN201610023812 A CN 201610023812A CN 105641511 A CN105641511 A CN 105641511A
- Authority
- CN
- China
- Prior art keywords
- herba
- chinese medicine
- medicine composition
- parts
- fici pumilae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 claims description 43
- 239000002775 capsule Substances 0.000 claims description 18
- 241001164374 Calyx Species 0.000 claims description 17
- 244000064622 Physalis edulis Species 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000012467 final product Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 238000007493 shaping process Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 abstract description 2
- 239000010436 fluorite Substances 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 241000218093 Phedimus aizoon Species 0.000 abstract 1
- 241001431534 Pogonatherum crinitum Species 0.000 abstract 1
- 230000009194 climbing Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- -1 fluidizer Substances 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 206010017553 Furuncle Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000010557 Lipid storage disease Diseases 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000021551 crystal sugar Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a Chinese medicine composition for treating a female climacteric syndrome and belongs to the field of Chinese medicine treatment of a climacteric syndrome. The Chinese medicine composition for treating the female climacteric syndrome is prepared from herba lophatheri, common leafflower herbs, pogonatherum crinitum, fluorite, climbing figs, sedum aizoon and rhizoma polygoni cuspidati. The Chinese medicine composition is prepared into an appropriate clinical preparation according to a Chinese medicine common preparation method. The Chinese medicine composition has the functions of nourishing the liver and kidneys and nourishing the blood for tranquilization; clinical treatment effects show that the Chinese medicine composition has a definite and reliable treatment effect on female climacteric syndrome, treats both symptoms and root causes, and is safe to apply clinically and free of any toxic and side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition treating female climacteric syndrome and its production and use, belong to the treatment by Chinese herbs field of climacteric syndrome.
Background technology
Female climacteric syndrome is that women ovarian function failed gradually to the transition period being wholly absent, female climacteric syndrome is multiple to be born between 40-60 year, owing to physiology and psychology change and a series of clinical symptoms of occurring, common warm sweating, irritable, palpitation and insomnia or melancholy forgetful etc. According to clinical manifestation, primary disease belongs to the category of " menopausal syndrome " of Chinese medicine. Primary disease is that women is before and after menopause, kidney qi is exhaustion gradually, virtual loss is appointed in punching, asthenia of essence and blood, menses is gradually exhausted, and menstruation will disconnected and physiological change that the menopause that arrives occurs, but some women is due to the impact of body constitution or Nervous and Mental Factors and other factors, for the moment do not adapt to these physiological changies, make negative and positive disequilibrium, internal organs QI and blood functional disorder and the disorderly syndrome of a series of functions of occurring.
The medicine treating female climacteric syndrome at present has a lot, and based on Western medicine, but Western medicine has side effect mostly. And Chinese materia medica is as the traditional medicine of China, there is treating both the principal and secondary aspects of a disease, act on advantage strong, instant effect, lasting medicine, and there is no dependency, drug resistance and toxic and side effects, therefore, develop a kind of Chinese medicine composition that female climacteric syndrome is had definite therapeutic effect, will have highly important clinical meaning.
Summary of the invention
The technical problem to be solved is to provide a kind of Chinese medicine composition treating female climacteric syndrome, and this Chinese medicine composition is fast to responding well to treatment of female climacteric syndrome, determined curative effect, have no side effect.
The preparation method that another technical problem to be solved by this invention is to provide a kind of described Chinese medicine composition.
For solving above-mentioned technical problem, the technical solution used in the present invention is:
First the present invention discloses a kind of Chinese medicine composition treating female climacteric syndrome, including following crude drug: Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati.
The weight portion of each crude drug is: Herba Lophatheri 45-50 part, Herba Phyllanthi Urinariae 35-45 part, Herba Melicae Scabrosae 35-45 part, Fluoritum 25-35 part, Caulis fici pumilae (Fructus Fici Pumilae) 25-35 part, Herba sedi kamtschatici 10-20 part, Rhizoma Polygoni Cuspidati 6-10 part;
Preferably, the weight portion of each crude drug is Herba Lophatheri 47 parts, Herba Phyllanthi Urinariae 40 parts, Herba Melicae Scabrosae 40 parts, Fluoritum 30 parts, Caulis fici pumilae (Fructus Fici Pumilae) 30 parts, Herba sedi kamtschatici 15 parts, Rhizoma Polygoni Cuspidati 8 parts.
Herba Lophatheri is the herb of grass Herba Lophatheri. Nature and flavor: sweet light, cold. Enter the heart, kidney two warp. Function cures mainly: clearing away heart-fire, heat clearing away and restlessness relieving, diuresis. Control calentura thirsty, vexed, hot urination, stranguria with turbid discharge, erosion of the oral mucosa tongue boil, gingival swelling and pain
Herba Phyllanthi Urinariae is herb or the whole herb with root of euphorbia plant Cacumen Securinegae Suffruticosae. Nature and flavor: sweetness and bitterness are cool. Enter liver, lung two warp. Function cures mainly: calming liver and clearing heat, promoting diuresis to remove toxic substance. Control enteritis, dysentery, infectious hepatitis, oedema due to nephritis, urinary tract infection, infantile malnutrition, acute catarrhal conjunctivitis corneal nebula, aphtha head sore, innominate toxic swelling.
Herba Melicae Scabrosae is the herb of grass Herba rutae. Nature and flavor: sweet are cool. Function cures mainly: relieving stranguria by diuresis, heat clearing away. Control urinary tract infection, oedema due to nephritis, cat fever, icterohepatitis, diabetes.
Fluoritum is the Ore of halogenide class mineral fluorite. Nature and flavor: sweet, temperature. Enter the heart, Liver Channel. Function cures mainly: relieving palpitation, calms the nerves, lowering the adverse flow of QI, warm uterus. Controlling asthenia palpitation with fear, cough with dyspnea, women's sea of blood deficiency and coldness is infertile.
Caulis fici pumilae (Fructus Fici Pumilae) is the stem of moraceae plants Caulis fici pumilae (Fructus Fici Pumilae), leaf. Nature and flavor: acid are flat. Function cures mainly: dispel the wind, and dampness removing is invigorated blood circulation, removing toxic substances. Control phoenix pain of dampness syndrome, dysentery, gonorrhea, traumatic injury, carbuncle furuncle.
Herba sedi kamtschatici is herb or the root of crassulaceae plants Herba sedi kamtschatici. Nature and flavor: acid are flat. Enter the heart, liver, spleen three warp. Function cures mainly: invigorate blood circulation, hemostasis, mind calming, dampness removing, detumescence, removing toxic substances. Control traumatic injury, hemoptysis, spit blood, have blood in stool, cardiopalmus, carbuncle.
Ground is the herb on Melastomateae plants ground. Nature and flavor: sweet micro-puckery are slightly cool. Enter liver,kidney,spleen, lung four warp. Function cures mainly: promoting blood circulation and hemostasis, heat-clearing and toxic substances removing. Control dysmenorrhea, puerperal abdonimal pain, metrorrhagia, leukorrhagia, have blood in stool, dysentery, carbuncle, furuncle.
Rhizoma Polygoni Cuspidati is the rhizome of polygonaceae plant Rhizoma Polygoni Cuspidati. Nature and flavor: bitter are flat. Function cures mainly: dispel the wind, dampness removing, and removing blood stasis with potent drugs stimulates the menstrual flow. Dispelling the wind and dampness pathogens bones and muscles pain, jaundice due to damp-heat, stranguria with turbid discharge leukorrhagia, women's amenorrhea, lochiostasis, lump in the abdomen, anal fistula hematochezia. Injury from falling down, scalds, malignant boil tinea.
Chinese medicine composition of the present invention is based on inventor to the pathogenetic research of deep layer of female climacteric syndrome and Therapeutic Principle thereof, simultaneously according to inventor's clinical experience for many years and pharmaceutical research achievement, the depressed liver-energy dispersing and QI regulating filtered out, blood circulation promoting and blood stasis dispelling, nourishing the liver and kidney, assistant helps the crude drug of kidney yang, forms according to certain weight proportion prescription.
The present invention further discloses a kind of Chinese medicine composition treating female climacteric syndrome, including following crude drug: Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici, Rhizoma Polygoni Cuspidati, Herba Abutili, Calyx seu fructus physalis and Herba Vernoniae Cinereae.
The weight portion of each crude drug is: Herba Lophatheri 45-50 part, Herba Phyllanthi Urinariae 35-45 part, Herba Melicae Scabrosae 35-45 part, Fluoritum 25-35 part, Caulis fici pumilae (Fructus Fici Pumilae) 25-35 part, Herba Abutili 25-35 part, Calyx seu fructus physalis 10-20 part, Herba sedi kamtschatici 10-20 part, Rhizoma Polygoni Cuspidati 6-10 part, Herba Vernoniae Cinereae 6-10 part;
Preferably, the weight portion of each crude drug is: Herba Lophatheri 47 parts, Herba Phyllanthi Urinariae 40 parts, Herba Melicae Scabrosae 40 parts, Fluoritum 30 parts, Caulis fici pumilae (Fructus Fici Pumilae) 30 parts, Herba Abutili 30 parts, Calyx seu fructus physalis 15 parts, Herba sedi kamtschatici 15 parts, Rhizoma Polygoni Cuspidati 8 parts, Herba Vernoniae Cinereae 8 parts.
Herba Abutili is herb or the leaf of Malvaceae plant Herba Abutili. Hardship, flat.Nature and flavor: function cures mainly: herb: removing toxic substances, dispel the wind. Control dysentery, otitis media, tinnitus, deafness, joint aches. "
Calyx seu fructus physalis is the herb of plant of Solanaceae Calyx seu fructus physalis. Nature and flavor: bitter, cold. Enter lung, spleen two warp. Function cures mainly: heat clearing away, removing toxic substances, diuresis. Control heat syndrome cough, pharyngalgia, jaundice, dysentery, edema, furuncle, erysipelas.
Herba Vernoniae Cinereae is the herb of feverfew Herba Vernoniae Cinereae. Nature and flavor: bitter are cool. Function cures mainly: heat clearing away, dehumidifying, removing toxic substances. Control fever caused by exogenous pathogens, acute icterohepatitis, damp-heat diarrhea, furuncle swelling toxin.
Female climacteric syndrome is had certain therapeutic effect by the Chinese medicine composition that the present invention is prepared by Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati, and effective percentage reaches 71.0%. The basis of Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati with the addition of following 6 groups of medicines respectively: (1) Radix Curcumae, Fructus Tritici Levis, Folium Mori; (2) Radix Glycyrrhizae, Semen Sesami Nigrum, crystal sugar; (3) Radix Salviae Miltiorrhizae, Cortex Albiziae, Cortex Lycii; (4) Herba Abutili, Calyx seu fructus physalis, Herba Vernoniae Cinereae; (5) Semen Ziziphi Spinosae, Caulis Polygoni Multiflori, Fructus Rosae Laevigatae; (6) Radix Polygalae, Rhizoma Acori Graminei, Spica Prunellae; Above-mentioned 6 groups of pharmaceutical compositions are prepared Chinese medicine composition respectively, investigates its therapeutic effect to female climacteric syndrome. Test result indicate that, Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati basis are added Herba Abutili, Calyx seu fructus physalis, Herba Vernoniae Cinereae to the effective percentage of patient up to 98.0%, be significantly higher than other combination. Illustrate that Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati have definite Synergistic effect together with Herba Abutili, Calyx seu fructus physalis, Herba Vernoniae Cinereae compatibility, be effectively increased the effective percentage for the treatment of female climacteric syndrome. By contrast, by Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati together with other several drugs compatibility after, for improve female climacteric syndrome therapeutic effect effect inconspicuous.
The each medicine compatibility of the present invention plays the effect with nourishing the liver and kidney, nourishing blood to tranquillize the mind together. Chinese medicine composition of the present invention is for female climacteric syndrome treating both the principal and secondary aspects of a disease, and clinical observation on the therapeutic effect confirms, Chinese medicine composition of the present invention is reliable for female climacteric syndrome determined curative effect, true. Chinese medicine composition of the present invention is nontoxic, safe and reliable, has no adverse reaction after taking, Clinical practice safety.
Each taste crude drug used by the present invention can be commercially available at pharmacy.
In the present invention on drug composition basis, add suitable adjuvant or carrier and be prepared into the suitable clinical preparation for the treatment of female climacteric syndrome according to Chinese medicine conventional formulation method; It is preferably oral formulations.
Described oral formulations includes pill, powder, granule, capsule, tablet, oral liquid or drop pill.
Described carrier or adjuvant refer to carrier or the adjuvant of pharmaceutical field routine, for instance: diluent, agent of bursting apart, lubricant, excipient, binding agent, fluidizer, filler, surfactant etc.; Furthermore it is also possible to add other adjuvant in the composition, such as flavouring agent and sweeting agent. Described diluent can be the composition of one or more increase tablet weight and volume, and conventional diluent includes lactose, starch, pregelatinized Starch, microcrystalline Cellulose, sorbitol, mannitol and inorganic calcium salt etc.; Most common of which is lactose, starch, microcrystalline Cellulose.Described disintegrating agent can be crospolyvinylpyrrolidone, one or more mixture in cross-linking sodium carboxymethyl cellulose, alginic acid, microcrystalline Cellulose; Wherein with crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose is preferred. Described lubricant includes stearic acid, sodium stearate, magnesium stearate, calcium stearate, Polyethylene Glycol, Pulvis Talci, one or more mixture in hydrogenated vegetable oil; Wherein most widely suited with magnesium stearate. Described binding agent can be one or more compositions being conducive to granulating; Can be starch slurry, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, it is preferred with the ethanol water of polyvinylpyrrolidone. Described fluidizer can be one or more mixture in micropowder silica gel, Pulvis Talci, magnesium trisilicate. Described surfactant can improve wettability for one or more and increase the composition of drug-eluting, commonly uses as sodium lauryl sulphate.
A kind of preparation method of Chinese medicine composition of the present invention, comprises the following steps: after being weighed by described weight by each crude drug of the present invention, pulverizes, sieve (can be such as 200-300 mesh sieve), to obtain final product. It is of course also possible to after each crude drug is pulverized, add the adjuvant needed for preparations shaping or excipient, conventionally prepare into required dosage form.
The another kind of preparation method of Chinese medicine composition of the present invention: weigh each crude drug by described weight portion; By each crude drug soak by water, merging decoction liquor, filter, filtrate is condensed into clear paste, adds adjuvant or excipient, the preparations shaping of preparations shaping, to obtain final product.
The usage of Chinese medicine composition of the present invention and consumption: the dosage of the present invention depends on the factors such as concrete dosage form, the age of patient, health status. As guidance: usage and dosage: capsule, every seed lac wafer is containing 0.6 gram of crude drug, and oral 1 to 2 every time, 3 times on the one, the morning, noon and afternoon respectively once, 10 days are a course for the treatment of, generally take 2-3 the course for the treatment of.
Technical solution of the present invention compared with prior art, has the advantages that
The compatibility of Chinese medicine composition of the present invention is reasonable, it is possible to significantly improve the effective percentage for the treatment of female climacteric syndrome, determined curative effect. Chinese medicine composition of the present invention is pure Chinese medicinal preparation, and treating both the principal and secondary aspects of a disease has no side effect, and preparation technology is simple, has a good application prospect.
Detailed description of the invention
Below in conjunction with specific embodiment further describe the present invention, advantages of the present invention and feature will be with describe and apparent. It should be understood that described embodiment is only exemplary, the scope of the present invention is not constituted any restriction. It will be understood by those skilled in the art that and the details of technical solution of the present invention and form can be modified or replace lower without departing from the spirit and scope of the present invention, but these amendments or replacement each fall within protection scope of the present invention.
The preparation of embodiment 1 capsule
Each crude drug is weighed: Herba Lophatheri 45g, Herba Phyllanthi Urinariae 35g, Herba Melicae Scabrosae 35g, Fluoritum 25g, Caulis fici pumilae (Fructus Fici Pumilae) 25g, Herba sedi kamtschatici 10g, Rhizoma Polygoni Cuspidati 6g by following weight; By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
The preparation of embodiment 2 capsule
Each crude drug is weighed: Herba Lophatheri 50g, Herba Phyllanthi Urinariae 45g, Herba Melicae Scabrosae 45g, Fluoritum 35g, Caulis fici pumilae (Fructus Fici Pumilae) 35g, Herba sedi kamtschatici 20g, Rhizoma Polygoni Cuspidati 10g by following weight;By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
The preparation of embodiment 3 capsule
Each crude drug is weighed: Herba Lophatheri 47g, Herba Phyllanthi Urinariae 40g, Herba Melicae Scabrosae 40g, Fluoritum 30g, Caulis fici pumilae (Fructus Fici Pumilae) 30g, Herba sedi kamtschatici 15g, Rhizoma Polygoni Cuspidati 8g by following weight; By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
The preparation of embodiment 4 capsule
Each crude drug is weighed: Herba Lophatheri 45g, Herba Phyllanthi Urinariae 35g, Herba Melicae Scabrosae 35g, Fluoritum 25g, Caulis fici pumilae (Fructus Fici Pumilae) 25g, Herba Abutili 25g, Calyx seu fructus physalis 10g, Herba sedi kamtschatici 10g, Rhizoma Polygoni Cuspidati 6g, Herba Vernoniae Cinereae 6g by following weight; By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
The preparation of embodiment 5 capsule
Each crude drug is weighed by following weight; Herba Lophatheri 50g, Herba Phyllanthi Urinariae 45g, Herba Melicae Scabrosae 45g, Fluoritum 35g, Caulis fici pumilae (Fructus Fici Pumilae) 35g, Herba Abutili 35g, Calyx seu fructus physalis 20g, Herba sedi kamtschatici 20g, Rhizoma Polygoni Cuspidati 10g, Herba Vernoniae Cinereae 10g; By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
The preparation of embodiment 6 capsule
Each crude drug is weighed: Herba Lophatheri 47g, Herba Phyllanthi Urinariae 40g, Herba Melicae Scabrosae 40g, Fluoritum 30g, Caulis fici pumilae (Fructus Fici Pumilae) 30g, Herba Abutili 30g, Calyx seu fructus physalis 15g, Herba sedi kamtschatici 15g, Rhizoma Polygoni Cuspidati 8g, Herba Vernoniae Cinereae 8g by following weight; By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
Experimental example 1 applies the clinical observation on the therapeutic effect test of traditional Chinese medicine composition for treating female climacteric syndrome of the present invention
One, physical data:
700 example patients all meet the diagnostic criteria of female climacteric syndrome, and patient is randomly divided into 7 groups, often organize 100 examples; 7 groups of no significant differences on sex, age, the course of disease and coincident with severity degree of condition. Diagnostic criteria: menoxenia, hectic fever is flushing, warms sweating, irritable, palpitation and insomnia, and head uncomfortable in chest adds, abnormal emotion-thought, neural, mental disorder, hypomnesis, cardiovascular and lipoidosis, motor system degeneration etc.
Two, prepared by medicine
Chinese medicine composition 1: weigh each crude drug according to following weight: Herba Lophatheri 47g, Herba Phyllanthi Urinariae 40g, Herba Melicae Scabrosae 40g, Fluoritum 30g, Caulis fici pumilae (Fructus Fici Pumilae) 30g, Herba sedi kamtschatici 15g, Rhizoma Polygoni Cuspidati 8g;
By above-mentioned each crude drug boiling secondary, first time adds the water of 4 times of weight, decocts 2 hours, and second time adds the water of 3 times of weight, decocts 1.5 hours; Decoction liquor being merged, filter, filtrate is concentrated into the clear paste that relative density is 1.17-1.19 (60 DEG C); Add appropriate amount of starch, mixing, dry, pulverize, add appropriate amount of ethanol and make granule, dry, granulate, fill capsule, to obtain final product.
Chinese medicine composition 2: add Radix Curcumae 30g, Fructus Tritici Levis 15g, Folium Mori 8g on Chinese medicine composition 1 basis;
Chinese medicine composition 3: add Radix Glycyrrhizae 30g, Semen Sesami Nigrum 15g, crystal sugar 8g on Chinese medicine composition 1 basis;
Chinese medicine composition 4: add Radix Salviae Miltiorrhizae 30g, Cortex Albiziae 15g, Cortex Lycii 8g on Chinese medicine composition 1 basis;
Chinese medicine composition 5: add Herba Abutili 30g, Calyx seu fructus physalis 15g, Herba Vernoniae Cinereae 8g on Chinese medicine composition 1 basis;
Chinese medicine composition 6: add Semen Ziziphi Spinosae 30g, Caulis Polygoni Multiflori 15g, Fructus Rosae Laevigatae 8g on Chinese medicine composition 1 basis;
Chinese medicine composition 7: add Radix Polygalae 30g, Rhizoma Acori Graminei 15g, Spica Prunellae 8g on Chinese medicine composition 1 basis;
The preparation method of Chinese medicine composition 2-7 is with Chinese medicine composition 1.
Three, Therapeutic Method
With the capsule of above-mentioned Chinese medicine composition 1-7, above-mentioned 7 groups of female patient of climacteric syndrome are treated respectively; Oral, one time 2 (0.6g crude drug/grain), 3 times on the one, the morning, noon and afternoon respectively once, 10 days are a course for the treatment of, 2-3 the course for the treatment of of general treatment; Other related drugs and other treatment is withdrawn during taking medicine.
Four, efficacy assessment standard
Cure: above-mentioned symptom all disappears;
Effective: above-mentioned symptom substantially alleviates or partial disappearance;
Invalid: by above-mentioned symptom after treating without alleviating or increasing the weight of.
Effective percentage: [(curing number of cases+effective number of cases)/total case load] �� 100%.
Five, clinical observation result
Clinical observation result is in Table 1.
The statistical result of the different traditional Chinese medicine composition for treating female climacteric syndrome of table 1
It is shown that female climacteric syndrome is had certain therapeutic effect by the Chinese medicine composition 1 prepared by Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati, effective percentage reaches 71.0%. On Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati basis, add Herba Abutili, Calyx seu fructus physalis, Herba Vernoniae Cinereae, the effective percentage for the treatment of female climacteric syndrome is significantly improved, reaches 98.0%.
These results suggest that, there is between Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati and Herba Abutili, Calyx seu fructus physalis, Herba Vernoniae Cinereae significant synergistic function, its compatibility can be significantly improved the effective percentage for the treatment of female climacteric syndrome together. By contrast, by Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati together with other several drugs compatibility after, for improve female climacteric syndrome therapeutic effect effect inconspicuous. Safety observations finds, it does not have observe any clinical adverse, it was shown that Chinese medicine composition clinical practice of the present invention is safe and free of toxic and side effects.
The effect observation of test example 2 traditional Chinese medicine composition for treating female climacteric syndrome
By clinical diagnosis be female patient of climacteric syndrome 87 example (clinical symptoms: (1) menoxenia: menstruation often postpones, even some months is just risen once, through amount also gradually decrease; (2) battle array hot flush: some women within climacteric owing to the level of estrogen declines, in blood, calcium level also declines to some extent, have a burst of position to generate heat, blush, perspire, with dizzy, nervous, the persistent period be one or two minute or 12 minutes-15 minutes not etc.;(3) cardiovascular and lipoidosis: it is possible that coronary heart disease, diabetes; (4) neural, mental disorder: blood pressure fluctuates more apparent up and down, it is possible to instability of being in a bad mood, emotional, personality change, hypomnesis etc.; (5) motor system is degenerated: waist, back of the body limbs pain occur, scapulohumeral periarthritis, cervical spondylosis occurs in some women. ) take capsule prepared by the embodiment of the present invention 6, every day 3 times, each 2,10 days be a course for the treatment of, altogether 3 courses for the treatment of of treatment.
Final healing 65 examples, effective 21 examples, total effective rate reaches 98.9%; And during medication, all do not find obvious adverse reaction.
Claims (10)
1. the Chinese medicine composition treating female climacteric syndrome, it is characterised in that include following crude drug: Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici and Rhizoma Polygoni Cuspidati.
2. the Chinese medicine composition described in claim 1, it is characterized in that, the weight portion of each crude drug is: Herba Lophatheri 45-50 part, Herba Phyllanthi Urinariae 35-45 part, Herba Melicae Scabrosae 35-45 part, Fluoritum 25-35 part, Caulis fici pumilae (Fructus Fici Pumilae) 25-35 part, Herba sedi kamtschatici 10-20 part, Rhizoma Polygoni Cuspidati 6-10 part.
3. the Chinese medicine composition described in claim 2, it is characterised in that the weight portion of each crude drug is: Herba Lophatheri 47 parts, Herba Phyllanthi Urinariae 40 parts, Herba Melicae Scabrosae 40 parts, Fluoritum 30 parts, Caulis fici pumilae (Fructus Fici Pumilae) 30 parts, Herba sedi kamtschatici 15 parts, Rhizoma Polygoni Cuspidati 8 parts.
4. the Chinese medicine composition treating female climacteric syndrome, it is characterised in that include following crude drug: Herba Lophatheri, Herba Phyllanthi Urinariae, Herba Melicae Scabrosae, Fluoritum, Caulis fici pumilae (Fructus Fici Pumilae), Herba sedi kamtschatici, Rhizoma Polygoni Cuspidati, Herba Abutili, Calyx seu fructus physalis and Herba Vernoniae Cinereae.
5. the Chinese medicine composition described in claim 4, it is characterized in that, the weight portion of each crude drug is: Herba Lophatheri 45-50 part, Herba Phyllanthi Urinariae 35-45 part, Herba Melicae Scabrosae 35-45 part, Fluoritum 25-35 part, Caulis fici pumilae (Fructus Fici Pumilae) 25-35 part, Herba Abutili 25-35 part, Calyx seu fructus physalis 10-20 part, Herba sedi kamtschatici 10-20 part, Rhizoma Polygoni Cuspidati 6-10 part, Herba Vernoniae Cinereae 6-10 part.
6. the Chinese medicine composition described in claim 5, it is characterized in that, the weight portion of each crude drug is: Herba Lophatheri 47 parts, Herba Phyllanthi Urinariae 40 parts, Herba Melicae Scabrosae 40 parts, Fluoritum 30 parts, Caulis fici pumilae (Fructus Fici Pumilae) 30 parts, Herba Abutili 30 parts, Calyx seu fructus physalis 15 parts, Herba sedi kamtschatici 15 parts, Rhizoma Polygoni Cuspidati 8 parts, Herba Vernoniae Cinereae 8 parts.
7. the Chinese medicine composition described in claim 1 to 6 any one, it is characterised in that be prepared into the clinical preparation being suitable for according to Chinese medicine conventional formulation method, it is preferred to oral formulations.
8. the Chinese medicine composition described in claim 7, it is characterised in that described oral formulations includes pill, powder, granule, capsule, tablet, oral liquid or drop pill.
9. prepare the method for Chinese medicine composition described in claim 1 to 6 any one for one kind, it is characterised in that comprise the following steps: weigh each crude drug; By each crude drug soak by water, merging decoction liquor, filter, filtrate is condensed into clear paste, adds adjuvant or excipient, the preparations shaping of preparations shaping, to obtain final product.
10. the purposes in the medicine of preparation treatment female climacteric syndrome of the Chinese medicine composition described in claim 1 to 6 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023812.7A CN105641511A (en) | 2016-01-14 | 2016-01-14 | Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023812.7A CN105641511A (en) | 2016-01-14 | 2016-01-14 | Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105641511A true CN105641511A (en) | 2016-06-08 |
Family
ID=56487331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610023812.7A Pending CN105641511A (en) | 2016-01-14 | 2016-01-14 | Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641511A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055835A (en) * | 2015-08-07 | 2015-11-18 | 苏州神林堂中医药研究所 | Traditional Chinese medicine composition used for treating female menopausal syndrome |
-
2016
- 2016-01-14 CN CN201610023812.7A patent/CN105641511A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055835A (en) * | 2015-08-07 | 2015-11-18 | 苏州神林堂中医药研究所 | Traditional Chinese medicine composition used for treating female menopausal syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN104288701A (en) | Traditional Chinese medicine composition for treating cholecystitis | |
| CN104225215A (en) | Traditional Chinese medicine for treating insomnia | |
| CN105535574A (en) | Traditional Chinese medicine composition capsule for mitigating side effects of chemotherapy for tumor patient | |
| CN103169798A (en) | Chinese medicinal composition for treating meniere disease and preparation method thereof | |
| CN103432412B (en) | Medicament for treating hyperplasia of mammary glands and preparation method thereof | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN104857366A (en) | Preoperative intervention medicine composition for neurosurgery and application thereof | |
| CN103977281A (en) | Traditional Chinese medicine composition for treating female endocrine disorders and preparation method thereof | |
| CN103071076B (en) | Traditional Chinese medicament composition for promoting recovery after cesarean section by lavipeditum nursing and application | |
| CN104784538A (en) | Chinese medicinal preparation for treating diabetes and preparation method | |
| CN104189668A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105213887A (en) | One is used for the treatment of glaucomatous Chinese medicine composition | |
| CN100431584C (en) | Chinese medicinal formulation for caring and enlarging breast | |
| CN104606661A (en) | Traditional Chinese medicinal galactagogue for treating hypogalactia after cesarean delivery and preparation method of galactagogue | |
| CN105641511A (en) | Chinese medicine composition for treating female climacteric syndrome and preparation method and application thereof | |
| CN102988883B (en) | Medicament for treating pneumonia and preparation method of medicament | |
| CN102327423A (en) | Chinese patent drug and Chinese decoction capable of effectively treating climacteric syndromes | |
| CN105998781A (en) | Pharmaceutical composition for treating acute gastroenteritis | |
| CN105412706A (en) | Traditional Chinese medicine composition for treating female endocrine dyscrasia | |
| CN104825892A (en) | Traditional Chinese medicine preparation for treating ovulatory bleeding and preparation method of traditional Chinese medicine preparation | |
| CN104474147A (en) | Traditional Chinese medicine for treating liver depression Qi stagnation type postpartum hypogalactia and preparation method of traditional Chinese medicine | |
| CN104524460A (en) | Pharmaceutical composition for preventing and treating acute nephritis and application thereof | |
| CN104274738A (en) | Traditional Chinese medicine for treating tinnitus and preparation method of the traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160608 |
|
| RJ01 | Rejection of invention patent application after publication |